2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
1. A method of treatment of psoriasis, ulcerative colitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of ischemia-reperfusion injury comprising administering a compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
A is selected from the group consisting of benzene, pyrrole, and indole;
labels 1 and 2 mark the relevant positions on the A ring;
the X atom is nitrogen or carbon;
R is a substituting group on the A ring selected from the group consisting of:
a group in the 3 (meta) position that is linear or branched C 1 -C 5 -alkyl, linear or branched C 2 -C 5 -alkenyl, linear or branched C 2 -C 5 -alkynyl, or substituted or not-substituted phenyl, linear or branched C 1 -C 5 -hydroxyalkyl, C 2 -C 5 -acyl, substituted or not-substituted benzoyl; and
a group in the 4 (para) position that is C 1 -C 5 alkyl, C 2 -C 5 -alkenyl, C 2 -C 5 -alkynyl, C 3 -C 6 -cycloalkyl, C 1 -C 5 -acyloxy, substituted or not-substituted benzoyloxy, C 1 -C 5 -acylamino, substituted or not-substituted benzoylamino, C 1 -C 5 -sulfonyloxy, substituted or not-substituted benzenesulfonyloxy, C 1 -C 5 -alkanesulfonylamino, substituted or not-substituted benzenesulfonylamino, C 1 -C 5 -alkanesulfonylmethyl, substituted or not-substituted benzenesulfonylmethyl, 2-furyl; 3-tetrahydrofuryl; 2-thiophenyl; 2-tetrahydrothiophenyl, C 1 -C 8 -alkanoyl, cycloalkanoyl or arylalkanoyl-C 1 -C 5 -alkylamino;
Hy is selected from the group consisting of methyl, ethyl, chlorine, bromine, methoxy and trifluoromethyl; and
YR′ is OH.
2. The method according to claim 1 , wherein R is 3′-benzoyl, 3′-(4-chloro-benzoyl), 3′-(4-methyl-benzoyl), 3′-acetyl, 3′-propionyl, 3′-isobutanoyl, 3′-ethyl, 3′-isopropyl, 4′-isobutyl, 4′-trifluoromethanesulphonyloxy, 4′-benzenesulphonyloxy, 4′-trifluoromethanesulphonylamino, 4′-benzenesulphonylamino, 4′-benzenesulphonylmethyl, 4′-acetyloxy, 4′-propionyloxy, 4′-benzoyloxy, 4′-acetylamino, 4′-propionylamino, or 4′-benzoylamino.
3. A method of treatment of psoriasis, ulcerative colitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of ischemia-reperfusion injury comprising administering a compound that is selected from the group consisting of:
(3-benzoyl-2-methylphenyl)acetic acid,
(2-chloro-3-propionylphenyl)acetic acid,
(3-isopropyl-2-methylphenyl)acetic acid,
(4-isobutyl-2-methylphenyl)acetic acid,
{2-methyl-4-[(phenylsulphonyl)amino]phenyl}acetic acid,
{2-methyl-4-[(trifluoromethanesulphonyl)amino]phenyl}acetic acid,
{2-chloro-4-[(trifluoromethanesulphonyl)oxy]phenyl}acetic acid,
(5-acetyl-1-methyl-1H-pyrrol-2-yl)acetic acid,
[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid,
(5-benzoyl-1-methyl-1H-pyrrol-2-yl)acetic acid,
[1-methyl-5-(4-chlorobenzoyl)-1H-pyrrol-2-yl]acetic acid,
(5-isobutyryl-1-methyl-1H-pyrrol-2-yl)acetic acid,
(1-benzoyl-2-methyl-1H-pyrrol-3-yl)acetic acid,
(1-benzoyl-2-chloro-1H-pyrrol-3-yl)acetic acid,
(1-benzoyl-2-methyl-1H-indol-3-yl)acetic acid,
[1-(4-chlorobenzoyl)-2-methyl-1H-indol-3-yl]acetic acid,
(1-isopropyl-2-methyl-1H-pyrrole[2,3-b]pyridin-3-yl)acetic acid, and
(3-benzoyl-2-methoxyphenyl)acetic acid.
4. The method of claim 1 , in which the compound of the formula (I) is administered in a dose from 1 to 1500 mg/day.